477 related articles for article (PubMed ID: 28624518)
1. Role of gut microbiota against calcium oxalate.
Sadaf H; Raza SI; Hassan SW
Microb Pathog; 2017 Aug; 109():287-291. PubMed ID: 28624518
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion.
Crivelli JJ; Mitchell T; Knight J; Wood KD; Assimos DG; Holmes RP; Fargue S
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33379176
[TBL] [Abstract][Full Text] [Related]
3. The role of the microbiome in kidney stone formation.
Mehta M; Goldfarb DS; Nazzal L
Int J Surg; 2016 Dec; 36(Pt D):607-612. PubMed ID: 27847292
[TBL] [Abstract][Full Text] [Related]
4. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
Torzewska A
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1144-53. PubMed ID: 24379255
[TBL] [Abstract][Full Text] [Related]
5. The genetic composition of Oxalobacter formigenes and its relationship to colonization and calcium oxalate stone disease.
Knight J; Deora R; Assimos DG; Holmes RP
Urolithiasis; 2013 Jun; 41(3):187-96. PubMed ID: 23632911
[TBL] [Abstract][Full Text] [Related]
6. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
Peck AB; Canales BK; Nguyen CQ
Urolithiasis; 2016 Feb; 44(1):45-50. PubMed ID: 26645869
[TBL] [Abstract][Full Text] [Related]
7. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
8. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
Tavasoli S; Alebouyeh M; Naji M; Shakiba Majd G; Shabani Nashtaei M; Broumandnia N; Basiri A
BJU Int; 2020 Jan; 125(1):133-143. PubMed ID: 31145528
[TBL] [Abstract][Full Text] [Related]
9. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
Abratt VR; Reid SJ
Adv Appl Microbiol; 2010; 72():63-87. PubMed ID: 20602988
[TBL] [Abstract][Full Text] [Related]
10. Impact of intestinal flora on calcium oxalate stones.
Wang C; Dong X; Yin X; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Nov; 46(11):1285-1289. PubMed ID: 34911864
[TBL] [Abstract][Full Text] [Related]
11. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
Siva S; Barrack ER; Reddy GP; Thamilselvan V; Thamilselvan S; Menon M; Bhandari M
BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
[TBL] [Abstract][Full Text] [Related]
12. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers.
Ticinesi A; Milani C; Guerra A; Allegri F; Lauretani F; Nouvenne A; Mancabelli L; Lugli GA; Turroni F; Duranti S; Mangifesta M; Viappiani A; Ferrario C; Dodi R; Dall'Asta M; Del Rio D; Ventura M; Meschi T
Gut; 2018 Dec; 67(12):2097-2106. PubMed ID: 29705728
[TBL] [Abstract][Full Text] [Related]
13. Calcium Oxalate Nephrolithiasis and Gut Microbiota: Not just a Gut-Kidney Axis. A Nutritional Perspective.
Ticinesi A; Nouvenne A; Chiussi G; Castaldo G; Guerra A; Meschi T
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32093202
[TBL] [Abstract][Full Text] [Related]
14. Analysis of commercial kidney stone probiotic supplements.
Ellis ML; Shaw KJ; Jackson SB; Daniel SL; Knight J
Urology; 2015 Mar; 85(3):517-21. PubMed ID: 25733259
[TBL] [Abstract][Full Text] [Related]
15. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist.
Daniel SL; Moradi L; Paiste H; Wood KD; Assimos DG; Holmes RP; Nazzal L; Hatch M; Knight J
Appl Environ Microbiol; 2021 Aug; 87(18):e0054421. PubMed ID: 34190610
[TBL] [Abstract][Full Text] [Related]
16. Probiotic properties of Oxalobacter formigenes: an in vitro examination.
Ellis ML; Dowell AE; Li X; Knight J
Arch Microbiol; 2016 Dec; 198(10):1019-1026. PubMed ID: 27449000
[TBL] [Abstract][Full Text] [Related]
17. Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.
Holmes RP; Knight J; Assimos DG
Urolithiasis; 2016 Feb; 44(1):27-32. PubMed ID: 26614109
[TBL] [Abstract][Full Text] [Related]
18. Oxalobacter formigenes: A new hope as a live biotherapeutic agent in the management of calcium oxalate renal stones.
Hiremath S; Viswanathan P
Anaerobe; 2022 Jun; 75():102572. PubMed ID: 35443224
[TBL] [Abstract][Full Text] [Related]
19. Association of dietary patterns with gut microbiota in kidney stone and non-kidney stone individuals.
Yuan C; Jin X; He Y; Liu Y; Xiang L; Wang K
Urolithiasis; 2022 Aug; 50(4):389-399. PubMed ID: 35460343
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis.
Miller AW; Choy D; Penniston KL; Lange D
Kidney Int; 2019 Jul; 96(1):180-188. PubMed ID: 31130222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
